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ABSTRACT 
Background: Hypertensive patients are at risk for increased hemodynamic 
response to tracheal intubation. Sympatholytic drugs administered during the 
preinduction period may prevent adverse vents. 
Objective: We assessed the effectiveness of a single preinduction IM bolus dose 
of dexmedetomidine (DMED) 2.5 Ftg/kg in attenuating hemodynamic responses to 
tracheal intubation and rapid-sequence anesthesia nduction in hypertensive pa- 
tients treated with angiotensin-converting e zyme inhibitors. 
Methods: Adult patients (American Society of Anesthesiologists classifica- 
tion II and III) with essential hypertension, scheduled for elective abdominal or 
gynecologic surgery, were enrolled in this randomized, double-blind, placebo- 
controlled study. Patients were assigned to i of 2 groups: the DMED group received 
IM DMED 2.5 i~g/kg and the placebo group received IM saline 0.9% 45 to 60 minutes 
before induction of anesthesia. General anesthesia was induced with thiopental, 
fentanyl, and vecuronium and maintained with a sevoflurane-nitrous xide-oxygen 
mixture. Hemodynamic values were recorded before (baseline) and after anesthe- 
sia induction, before endotracheal intubation, and 1, 3, and 5 minutes after intuba- 
tion. The patients were monitored for hypotension (systolic arterial pressure [SAP] 
decreased >25% from baseline or to <90 mm Hg) or bradycardia (heart rate [HR] 
decreased >25% from baseline or to <50 beats/min). 
Results: Nine hundred sixty patients were assessed for enrollment during a 
6-month period. Sixty patients (49 women, 11 men; mean [SD] age, 59.16 [8.39] years) 
were eligible for the study. There were no significant differences in baseline hemo- 
dynamic values between the groups. SAP and diastolic arterial pressure (DAP) 
before anesthesia nduction, 1 and 3 minutes after intubation, and DAP 1 minute 
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after intubation were significantly ower in the DMED group than in the placebo 
group (all, P < 0.05). There were no significant between-group differences in 
SAP or DAP 5 minutes after intubation. HR before anesthesia nduction, before 
intubation, and 1, 3, and 5 minutes after intubation were lower in the DMED 
group than in the control group (all, P < 0.05). In the DMED group, SAP after 
intubation, DAP before intubation, 3 and 5 minutes after intubation, HR before 
induction, before intubation, and 3 and 5 minutes after intubation were signifi- 
cantly decreased compared with baseline values (all, P < 0.05). In the control 
group, SAP at all times, DAP before intubation, 1, 3, and 5 minutes after 
intubation, HR before intubation, and 3 and 5 minutes after intubation were 
significantly decreased compared with baseline values (all, P < 0.05). Hypo- 
tension and bradycardia were observed together in 3 patients, and hypo- 
tension alone was observed in 1 patient 3 minutes after intubation in the 
DMED group; hypotension was observed in 1 patient at 3 minutes after intuba- 
tion in the control group. 
Conclusion: The results of this study suggest that IM DMED 2.5 gg/kg admin- 
istered 45 to 60 minutes before anesthesia induction attenuated, but did not 
completely prevent, hemodynamic responses to tracheal intubation in these 
patients with essential hypertension. (Curt Ther Res Clin Exp. 2007;68:292-302) 
Copyright © 2007 Excerpta Medica, Inc. 
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INTRODUCTION 
Tracheal intubation induces an increase in central and peripheral sym- 
pathetic activity that results in hypertension and a substantial increase 
in heart rate (HR) at the beginning of the operative period. 1,2 Because of 
marked stimulation of the sympathetic nervous system, drugs with the 
ability to modulate sympathic tone may be beneficial for patients at risk 
of hypertension. 1,2 c¢2-Adrenergic agonists have anesthetic-sparing, anal- 
gesic, sedative, anxiolytic, and sympatholyt ic effects, thereby preventing 
catecholamine r lease, hypertension, and tachycardia. 1,3-6 Sympatholysis 
achieved with IM dexmedetomidine (DMED) attenuates the catecholamine 
response to anesthesia induction and tracheal intubation. We hypothesize 
that plasma catecholamine concentration, HR, blood pressure (BP), and 
myocardial oxygen demand may be reduced by IM DMED, thereby possibly 
preventing cardiac adverse events (AEs). Although a search of MEDLINE 
(key terms: intramuscular, dexmedetomidine, and anesthesia induction) identi- 
fied several studies 1-8 regarding the use of DMED during the anesthesia, 
no previous study was performed on hypertensive patients. 
Our purpose was to investigate the effectiveness of preoperative admin- 
istration of IM DMED 2.5 pg/kg in attenuating hemodynamic responses during 
rapid-sequence anesthesia nduction and tracheal intubation in hypertensive 
patients treated with angiotensin-converting e zyme (ACE) inhibitors. 
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PATIENTS AND METHODS 
The study was approved by the Erciyes University Medical Faculty Ethics 
Committee, Kayseri, Turkey. Written informed consent was obtained from all 
patients prior to entering the study. The study was conducted in accordance with 
the principles of the Declaration of Helsinki 9and Good Clinical Practice. 1° 
During a 6-month period between September 2006 and March 2007, patients 
categorized as American Society of Anesthesiologists (ASA) classification II or 
II111 who had been diagnosed with essential hypertension (BP >140/90 mm Hg) 
>1 year before were eligible for the study. Eligibility was limited to patients aged 
40 to 70 years, who were scheduled for elective abdominal or gynecologic 
surgery, and who were being treated only with ACE inhibitors 1 day before 
surgery. The patients were randomly assigned in an equal ratio to receive IM 
DMED* 2.5 1Jg/kg or saline 0.9% (control group). 
Exclusion criteria were as follows: history of cardiac or pulmonary disease; 
pregnancy; morbid obesity; allergy to the study drug; sequelae due to hyper- 
tension (eg, retinopathy, renal insufficiency, left ventricular hypertrophy); and 
use of any antihypertensive medication except ACE inhibitors. 
All patients were monitored using electrocardiography, noninvasive blood 
pressure, pulse oximetry, airway gas levels, and end-tidal carbon dioxide concen- 
tration (Datex-Engstrom AS/3, Helsinki, Finland). Saline 8 mL/kg • h was admin- 
istered to all patients during the study. All hemodynamic data were measured 
at baseline, before induction, before intubation, and 1, 3, and 5 minutes after 
intubation by another observer who was blinded to treatment group. Serious 
AEs were defined as hypotension and bradycardia. 
Patients in the DMED group received IM DMED 2.5 btg/kg diluted to 5 mL with 
saline 0.9% and patients in the control group received 5 mL of IM saline 0.9% 
45 to 60 minutes before anesthesia induction. To maintain blinding, the experi- 
mental and control drugs were identical in appearance. 
After preoxygenation for 2 minutes, anesthesia was induced with thiopental 
sodium 5 mg/kg and fentanyl 2 1Jg/kg. Tracheal intubation was facilitated by 
vecuronium 0.1 mg/kg. After orotracheal intubation, general anesthesia was 
maintained with 1.5% to 2.0% sevoflurane in a mixture of 66% nitrous oxide 
and 33% oxygen and with intermittent 2-btg/kg bolus doses of IV fentanyl. At 
the end of surgery, residual neuromuscular block was reversed with IV atropine 
0.015 mg/kg and IV neostigmine 0.05 mg/kg. The tracheal tube was removed 
after adequate spontaneous ventilation was established. 
Hypotension was defined as a decrease in systolic arterial pressure (SAP) 
of >25% from baseline or SAP <90 mm Hg, and bradycardia was defined as a 
decrease in HR of >25% from baseline or HR <50 beats per minute. We planned 
to treat hypotension and bradycardia by decreasing the inhalation agent con- 
centration by 50% or by administering IV ephedrine 10 mg or IV atropine 0.5 mg, 
respectively. 
*Trademark: Precedex ® (Abbott Laboratories, Chicago, Illinois). 
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Statistical Analyses 
Assuming an c¢ risk of 0.05 and a [3 risk of 0.20, we calculated that >22 pa- 
tients should be included to provide a 90% power for each study group to detect 
a 20% change from baseline in SAP, diastolic arterial pressure (DAP), and HR. 
Normal distribution of data was determined using the Kolmogorov-Smirnov 
test. Results are presented as mean (SD). Parametric data were analyzed using 
unpaired Student t tests between groups. Analysis of variance was done for 
repeated measures within groups. Nonparametric data were analyzed using the 
Fisher exact test. P < 0.05 was considered significant. All statistical analyses were 
performed using Statistica 4.3 for Windows (Statsoft Inc., Tulsa, Oklahoma). 
RESULTS 
Nine hundred sixty patients were assessed for enrol lment during a 6-month 
period. Sixty patients (49 women, 11 men; mean [SD] age, 59.16 [8.39] years) 
were eligible for the study. All 60 patients were included in the statistical analy- 
ses. There were no significant differences between the groups in terms of age, 
weight, height, sex distribution, or ASA risk-class status (Table I). 
No significant differences were found in baseline SAP, DAP, and HR between 
the 2 groups (Tables II-IV). SAP and DAP before anesthesia induction, 1 and 
3 minutes after intubation, were significantly lower in the DMED group than in 
the placebo group (all, P < 0.05). There were no significant between-group dif- 
ferences in SAP or DAP 5 minutes after intubation. HR before anesthesia induc- 
tion, before intubation, and 1, 3, and 5 minutes after intubation was significantly 
lower in the DMED group than in the placebo group (all, P < 0.05). 
In the DMED group, SAP after intubation, DAP before intubation, 3 and 5 min- 
utes after intubation, HR before induction, before intubation, and 3 and 5 minutes 
after intubation were significantly decreased compared with baseline values (all, 
P < 0.05). 
In the placebo group, SAP at all times, DAP before intubation, 3, and 5 minutes 
after intubation, HR before intubation and 5 minutes after intubation were signifi- 
cantly decreased compared with baseline values (all, P < 0.05) (Table IV). 
SAP and DAP data are presented in Figure 1 and HR data are presented in 
Figure 2. In both groups, statistically significant increases were found in SAP 
and DAP at 1 and 3 minutes after intubation compared with before intubation 
(all, P < 0.05). Also, in both groups, HR 1 minute after intubation was higher 
than before intubation. In the placebo group, HR 3 minutes after intubation was 
significantly higher than before intubation (P < 0.05), but in the DMED group, 
HR 3 minutes after intubation was not significantly different. In the DMED 
group, no values were higher than at baseline (Tables II-IV). 
We observed hypotension and bradycardia in 3 patients and hypotension alone 
in 1 patient during the third minute after intubation in the DMED group. Hypo- 
tension was observed in 1 patient 3 minutes after intubation in the placebo group. 
No significant differences were found in prevalence of AEs between the groups. 
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Table I. Demographic  and clinical characteristics of hypertensive study patients ran- 
domized to receive dexmedetomid ine  (DMED) or placebo dur ing tracheal 
intubation and anesthesia induction (N -- 60).* 
DMED Group Placebo Group 
Variable (n = 30) (n = 30) ts8 P 
Age, mean (SD), y 59.9 (8.6) 58.4 (8.2) 0.67 0.50 
Weight, mean (SD), kg 75.6 (14.9) 80.4 (11.7) 1.39 0.16 
Height, mean (SD), cm 160.5 (8.6) 159.9 (8.1) 0.24 0.80 
Sex 0.016 0.25 
Female 26 23 
Male 4 7 
ASA Classification 0.04 0.39 
II 15 17 
III 15 13 
ASA = American Society of Anesthesiologists. 
*There were no significant between-group differences. 
Table II. Systolic arterial pressure (in mm Hg) by t reatment  group. Values are mean 
(SD). 
DMED Group Placebo Group 
Time (n = 30) (n = 30) ts8 P* 
Baseline 154.93 (19.05) 163.53 (14.67) 1.95 0.06 
Before induction 141.76 (19.56)t 162.23 (17.20)t 4.24 0.002 
Before intubation 108.06 (20.14)t~ 123.26 (24.26)t~ 2.64 0.01 
1 Minute after intubation 134.76 (27.08)t~§ 172.40 (30.05)t~§ 5.09 0.001 
3 Minutes after intubation 124.33 (22.74)t~§11 144.13 (35.31)t~§11 2.58 0.01 
5 Minutes after intubation 117.20 (21.78)t$11 128.86 (26.92)t$§11~ 1.84 0.07 
F 50.70 25.41 
P 0.001 0.001 
DMED = dexmedetomidine; F = 1 -way analysis of variance. 
*Intergroup significance. 
tp < 0.05 versus baseline. 
~P < 0.05 versus before induction. 
§P < 0.05 versus before intubation. 
lip < 0.05 versus 1 minute after intubation. 
qlp < 0.05 versus 3 minutes after intubation. 
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Table III. Diastol ic arter ia l  pressure (in mm Hg) by t reatment  group.  Values are  
mean (SD) .  
DMED Group Control Group 
Time (n = 30) (n = 30) ts8 P* 
Baseline 86.10 (12.14) 90.71 (19.17) 1.60 0.11 
Before induction 83.93 (13.78) 93.76 (13.93) 2.84 0.006 
Before intubation 67.56 (15.85) t* 75.33 (15.28) t* 1.93 0.05 
1 Minute after intubation 84.76 (19.70)§ 106.83 (22.15) t*§ 4.07 0.001 
3 Minutes after intubation 76.10 (16.61)t*§11 87.46 (22.71)t*§11 2.23 0.02 
5 Minutes after intubation 74.60 (15.74)t*§11 80.70 (15.28)t*§11 1.52 0.13 
F 28.35 10.10 
P 0.001 0.001 
DMED = dexmedetomidine; F = 1-way analysis of variance. 
*Intergroup significance. 
tp < 0.05 versus baseline. 
*P < 0.05 versus before induction. 
§P < 0.05 versus before intubation. 
lip < 0.05 versus 1 minute after intubation. 
Table IV. Heart rate by t reatment  group. Values are  mean (SD) beats per minute. 
DMED Group Control Group 
Time (n = 30) (n = 30) ts8 P* 
Baseline 86.90 (27.46) 83.3 (12.37) 0.65 0.51 
Before induction 79.93 (15.12)t 87.93 (15.26) 2.03 0.04 
Before intubation 73.43 (11.19)t* 79.40 (10.68)t* 2.13 0.03 
1 Minute after intubation 81.06 (12.77)§ 90.70 (15.06)§ 2.68 0.009 
3 Minutes after intubation 76.30 (10.96)t 84.56 (14.06)t§11 2.53 0.01 
5 Minutes after intubation 71.86 (8.17)t*11 78.73 (13.55)t*11~ 2.37 0.02 
F 12.00 6.75 
P 0.001 0.001 
DMED = dexmedetomidine; F = 1 -way analysis of variance. 
*Intergroup significance. 
tp < 0.05 versus baseline. 
*P < 0.05 versus before induction. 
§P < 0.05 versus before intubation. 
lip < 0.05 versus 1 minute after intubation. 
qlp < 0.05 versus 3 minutes after intubation. 
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Systolic arterial pressure (SAP) and diastolic arterial pressure (DAP) 
by treatment group in hypertensive patients randomized to receive 
dexmedetomidine (DMED) or placebo during tracheal intubation and 
anesthesia induction. *P ¢0.05/ersus placebo group for both SAP and DAP. 
DISCUSSION 
Hypertension is a common (1 in 5 adults) medical condition that must be 
assessed and managed in the perioperative period. 12 Perioperative stress 
induces a hormonal  response character ized by an increase in plasma concen- 
trations of catecholamines and cortisol. 13 Sympathetic activation leads to an 
increase in BP, HR, and energy expenditure, and thus to an increase in oxygen 
consumption. 14,15 Reduction of stress is desirable, especial ly for patients with 
cardiac risk factors. 16 Centrally acting a2-agonists have been shown to reduce 
the concentrat ion of circulating stress hormones. 17 
Anesthetic-sparing, analgesic, sedative, and sympatholyt ic  effects of DMED 
have been found in various studies. 14-19 Erkola et a119 reported a study involv- 
ing 192 women undergoing abdominal hysterectomy. Three different reatment 
groups (n = 64) were examined. One group received only IM DMED 2.5 Ftg/kg 
followed by placebo, the second group received IM DMED 2.5 Ftg/kg followed by 
IV fentanyl 1.5 Ftg/kg, and the third group received IM midazolam 0.08 mg/kg 
followed by IV fentanyl 1.5 Ftg/kg. The DMED/fentanyl combination was found 
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Fcjure 2. Heart rate (HR) bytreatment group in hypertensive patients randomized to 
receive dexmedetomidine (DMED) or placebo during tracheal intubation 
and anesthesia induction. *P <0.05zersus placebo group. 
to most significantly attenuate sympathetic activation during tracheal intuba- 
tion and to reduce the anesthetic requirement compared with both the placebo 
and midazolam groups. Intraoperatively and postoperatively, however, DMED- 
treated patients howed significantly more bradycardia than patients receiv- 
ing midazolam. Levanen et al 2° tested the effects of premedication with DMED 
2.5 i~g/kg (n = 20) and midazolam 0.07 mg/kg (n = 20) on patients undergoing 
minor surgery using ketamine as the primary anesthetic. DMED was associated 
with better hemodynamic control than midazolam during intubation. However, 
DMED was also more often associated with intraoperative and postoperative 
bradycardia. These findings agree with those of the present study. In the DMED 
group, we observed hypotension and bradycardia in 3 patients and hypoten- 
sion alone in 1 patient 3 minutes after intubation. These patients were success- 
fully treated with IV atropine 0.5 mg and ephedrine 10 mg. 
We did not determine the concentration of circulating stress hormones, 
while we did monitor SAP and DAP invasively; however, our findings uggest that 
DMED effectively attenuated hemodynamic stress responses during anesthesia 
induction and intubation without serious AEs. We observed significantly lower 
HR values before intubation to 5 minutes postintubation i the DMED group 
compared with the control group. In patients with cardiac risks, lower HR may 
be particularly helpful in reducing myocardial oxygen demand. 
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Talke et a121 investigated the effect of DMED on hemodynamic response 
during emergence from anesthesia n 41 patients undergoing vascular surgery. 
They studied the ability of DMED to attenuate he stress response during emer- 
gence from anesthesia, the period known to be associated with a significant 
perioperative stress response. Patients received either IV DMED (n = 22) or pla- 
cebo (n = 19) from 20 minutes before the induction of anesthesia until 48 hours 
after the end of surgery71 During emergence from anesthesia, DMED attenuated 
the increases in HR and plasma norepinephrine concentration. The percentage 
of time during which HR was within predetermined hemodynamic limits was 
significantly higher in the DMED-treated patients. Serious AEs were reported 
for 3 DMED-treated patients and 4 placebo patients. An episode of postopera- 
tive hypotension that resolved with the administration f IV fluids and a sinus 
pause during intubation that resolved spontaneously were possibly related to 
treatment with DMED. One patient in the placebo group died of multiple organ 
failure. 21 Our results regarding the attenuation f significant perioperative stress 
are consistent with these results. 
Unlike previous tudies, 19-21 we did not investigate he effectiveness of DMED 
on the stress response during emergence from anesthesia. In addition, we admin- 
istered IM DMED as a single dose because its elimination tl/2 is -2 hours. 22 Also, 
we completed all study protocols within the drug's duration of action. 
Tanaka and Nishikawa 23 and Handa et a124 reported that c~-adrenoceptor 
agonists ignificantly reduced both baseline sympathetic tone and pharma- 
cologically induced effects, such as activation of the sympathetic system by 
ketamine. In contrast, clonidine treatment before the administration f ephed- 
rine resulted in an augmented increase in BP. 2s The reason for this may be that 
c~-adrenoceptor agonists enhanced the peripheral action of catecholamines. 
We did not observe any hypertensive r sponse in our patients. 
CONCLUSION 
The results of this study suggest that IM DMED 2.5 FJg/kg administered 45 to 
60 minutes before anesthesia induction attenuated, but did not completely 
prevent, hemodynamic responses to tracheal intubation i  these patients with 
essential hypertension. 
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